Biotech & Pharmaceuticals

Abbvie offers to buy Allergan for $63 billion dollars as big drug makers look for new ways to grow. Meg Tirrell reports.

Shares of Bristol-Myers Squibb fell 7% Monday after the pharmaceutical giant announced that the proposed acquisition of Celgene will now close later than originally expected and will involve a divestiture of Celgene’s psoriasis drug.

The presidential hopefuls aren’t the only ones eyeing health-care issues for 2020. Large employers are putting together benefit plans for next year, and they are expecting the rise in employee health costs to hit a four-year high, in part, due to rising drug prices.

A pharmacy warned the Food and Drug Administration that it found a chemical believed to cause cancer in a widely used blood pressure medication, according to a filing from the federal agency.

Pfizer makes a $10 billion deal to expand its cancer lineup and its footprint in an area as known as a precision medicine. Meg Tirrell reports.

Our Meg Tirrell reports from Johnson & Johnson headquarters in New Jersey where the company’s CEO puts his focus on the pharmaceutical pipeline.

Johnson & Johnson outlined plans to grow its pharmaceutical business on Wednesday.

J&J CEO Alex Gorsky told CNBC that the company needs to focus on new innovations.

Shares of Biogen plummeted Thursday after the company halted the trial of Alzheimer’s disease drug aducanumab.

High profile CEOs in the drug industry testified about drug prices in front of a Senate committee. Ylan Mui reports.

“Like most Americans, I’m sick and tired of the blame game,” says Senate Finance Committee Chairman Chuck Grassley. “It’s time for solutions.”

Two new deals to the start the year and positive trial presentations at the J.P. Morgan Health Care conference, have breathed new life into some of last year’s biggest stock losers.

Biotech giant Amgen is lowering the price of its cholesterol medicine Repatha by almost 60 percent, following a similar move from its competitor, after both drugs failed to meet sales expectations.

Meg Tirrell reports on J&J’s relaunch of the iconic baby brand, which will have fewer chemicals and more natural ingredients.

J&J is still the global leader in the category, but says it needs to make a change to stem a sales decline.